Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1991-12-31
|
pubmed:abstractText |
We treated 109 patients with adult acute lymphoblastic leukemia (ALL) diagnosed by histochemical and immunologic techniques. Patients were excluded only for age greater than 50 years and Burkitt's leukemia. Treatment included a four-drug remission induction phase followed by alternating cycles of noncrossresistant chemotherapy and prolonged oral maintenance therapy. Eighty-eight percent of patients entered complete remission. With a median follow-up of 77 months (range, 48 to 111 months), 42% +/- 6% (SEM) of patients achieving remission are projected to remain disease-free at 5 years, and disease-free survival for all patients entered on study is 35% +/- 5%. Failure to achieve remission within the first 4 weeks of therapy and the presence of the Philadelphia chromosome are associated with a 100% risk of relapse. Remission patients with neither of these adverse features have a 48% +/- 6% probability of remaining in continuous remission for 5 years. Patients with T-cell phenotype have a favorable prognosis with 59% +/- 13% of patients achieving remission remaining disease-free compared with 31% +/- 7% of CALLA-positive patients. Intensive chemotherapy may produce prolonged disease-free survival in a sizable fraction of adults with ALL. Improved therapy is needed, especially for patients with adverse prognostic features.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
78
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2814-22
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1835410-Adult,
pubmed-meshheading:1835410-Antigens, CD,
pubmed-meshheading:1835410-Antigens, Differentiation,
pubmed-meshheading:1835410-Antigens, Neoplasm,
pubmed-meshheading:1835410-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:1835410-Drug Administration Schedule,
pubmed-meshheading:1835410-Humans,
pubmed-meshheading:1835410-Neprilysin,
pubmed-meshheading:1835410-Nervous System Neoplasms,
pubmed-meshheading:1835410-Philadelphia Chromosome,
pubmed-meshheading:1835410-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:1835410-Prognosis,
pubmed-meshheading:1835410-Survival Analysis
|
pubmed:year |
1991
|
pubmed:articleTitle |
Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report.
|
pubmed:affiliation |
Department of Medicine, University of California, San Francisco.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|